The mutation was found to be associated with breast cancer with an odds ratio (OR) of 1.86 [95% confidence interval (CI) 1.26–2.75, P = 0.0018], especially among triple-negative breast cancer [TNBC; estrogen (ER) and progesterone (PR) receptor and HER2 negative] cases (OR 3.56, 95% CI 1.81–6.98, P = 0.0002). Here, ESR1 is linked to breast carcinoma.